Disease progression in COVID-19 varies among patients infected with the SARS-CoV-2 virus. While most patients experience harmless symptoms, some patients suffer from severe illness. To assess whether the immune profile of ICU COVID-patients is specific for SARS-CoV-2 or is driven by a general inflammation also seen in non-SARS-CoV-2 pneumonia, blood samples from both kinds of patients and controls were taken. The samples were analyzed via longitudinal, high-dimensional single-cell spectral cytometry and algorithm-guided analysis to characterize their immune pattern. Results show that, besides some similarities in immune profile, in SARS-CoV-2 infections a special sort of T killer cells can serve as a predictive biomarker to assess the severeness of the disease even at an early point of time, leading to better monitoring and care of the patients.
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!